<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03208127</url>
  </required_header>
  <id_info>
    <org_study_id>2017P000653</org_study_id>
    <nct_id>NCT03208127</nct_id>
  </id_info>
  <brief_title>DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant</brief_title>
  <official_title>Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Liver Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center study for the donation of HCV-positive livers to HCV negative
      recipient patients, with preemptive, interventional treatment to prevent HCV transmission
      upon transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be selected based on diminished likelihood of receiving a liver from the
      waitlist within a period during which they would be likely to succumb to severe
      comorbidities. This will be determined in part through use of a patient's MELD score, listing
      status, and clinical judgment. To ensure maximal benefit for the recipient, only high quality
      donor livers will be accepted.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 21, 2017</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Undetectable HCV</measure>
    <time_frame>12 weeks post treatment</time_frame>
    <description>Negative HCV viral RNA at 12 weeks after the last dose of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability (based on number of adverse events and out of range lab values) of Sofosbuvir and Velpatisvir</measure>
    <time_frame>12 weeks</time_frame>
    <description>Safety and tolerability of sofosbuvir and velpatisvir in the liver transplant patient will be monitored by quantifying the number of treatment related adverse events per patient and evaluating out of range laboratory results as compared to baseline/pretreatment values per patient.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>End Stage Liver Disease</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Treatment with Sofosbuvir/Velpatisvir Fixed Dose Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks of HCV treatment with combination tablet of Sofosbuvir + Velatisvir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination treatment with Sofosbuvir and Velpatisvir fixed dose tablet</intervention_name>
    <description>HCV Treatment for 12 Weeks</description>
    <arm_group_label>Treatment with Sofosbuvir/Velpatisvir Fixed Dose Combination</arm_group_label>
    <other_name>Epclusa treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recipient is Age ≥ 18 years

          -  Met MGH transplant center criteria, listed for liver transplant

          -  HCV naïve

          -  Able to sign informed consent

        Exclusion Criteria:

          -  Pregnant or nursing (lactating) women

          -  HIV positivity

          -  Need for dual organ transplant

          -  Any contra-indication to liver transplantation per center protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond Chung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raymond Chung, MD</last_name>
    <phone>617-724-7562</phone>
    <email>RChung@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jenna Gustafson, MSc</last_name>
    <phone>617-724-3836</phone>
    <email>JLGustafson@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Masschusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenna L Gustafson, MS</last_name>
      <phone>617-724-3836</phone>
      <email>jlgustafson@partners.org</email>
    </contact>
    <contact_backup>
      <last_name>Raymond T Chung, MS</last_name>
      <email>rchung@partners.org</email>
    </contact_backup>
    <investigator>
      <last_name>Emily Bethea, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2017</study_first_submitted>
  <study_first_submitted_qc>July 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2017</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Raymond T. Chung, MD</investigator_full_name>
    <investigator_title>Director of Hepatology</investigator_title>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>Epclusa</keyword>
  <keyword>ESLD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Sofosbuvir-velpatasvir drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Coded data is anticipated to be shared with potential collaborators.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

